Cargando…

Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients

Psoriasis is a chronic immune-mediated inflammatory skin disorder affecting children and adults. To date no approved biomarkers for diagnosis of this disease and follow up of patients have been translated into clinical practice. Recently, extracellular vesicles (EVs) secreted by all cells and presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Paolino, Giovanni, Buratta, Sandra, Mercuri, Santo R., Pellegrino, Roberto M., Urbanelli, Lorena, Emiliani, Carla, Bertuccini, Lucia, Iosi, Francesca, Huber, Veronica, Brianti, Pina, Prezioso, Caterina, Di Nicola, Matteo R., Federici, Cristina, Lugini, Luana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234320/
https://www.ncbi.nlm.nih.gov/pubmed/35769256
http://dx.doi.org/10.3389/fcell.2022.923769
_version_ 1784736044728451072
author Paolino, Giovanni
Buratta, Sandra
Mercuri, Santo R.
Pellegrino, Roberto M.
Urbanelli, Lorena
Emiliani, Carla
Bertuccini, Lucia
Iosi, Francesca
Huber, Veronica
Brianti, Pina
Prezioso, Caterina
Di Nicola, Matteo R.
Federici, Cristina
Lugini, Luana
author_facet Paolino, Giovanni
Buratta, Sandra
Mercuri, Santo R.
Pellegrino, Roberto M.
Urbanelli, Lorena
Emiliani, Carla
Bertuccini, Lucia
Iosi, Francesca
Huber, Veronica
Brianti, Pina
Prezioso, Caterina
Di Nicola, Matteo R.
Federici, Cristina
Lugini, Luana
author_sort Paolino, Giovanni
collection PubMed
description Psoriasis is a chronic immune-mediated inflammatory skin disorder affecting children and adults. To date no approved biomarkers for diagnosis of this disease and follow up of patients have been translated into clinical practice. Recently, extracellular vesicles (EVs) secreted by all cells and present in almost all biological fluids are playing a crucial role in diagnosis and follow up of several diseases, including psoriasis. Since many psoriatic patients show altered plasma lipid profiles and since EVs have been involved in psoriasis pathogenesis, we studied the phospholipid profile of EVs, both microvesicles (MV) or exosomes (Exo), derived from plasma of psoriatic patients undergoing systemic biological treatment (secukinumab, ustekinumab, adalimumab), in comparison with EVs of untreated patients and healthy donors (HD). EVs were evaluated by immune electronmicroscopy for their morphology and by NanoSight for their amount and dimensions. EV phospholipid profiling was performed by High Resolution Liquid Chromatography-Mass Spectrometry and statistical Partial Least Squares Discriminant Analysis. Our results demonstrated that psoriatic patients showed a higher concentration of both MV and Exo in comparison to EVs from HD. The phospholipid profile of Exo from psoriatic patients showed increased levels of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol and lysoPC compared to Exo from HD. Sphingomyelin (SM) and phosphatidylinositol (PI) are the only phospholipid classes whose levels changed in MV. Moreover, the therapy with ustekinumab seemed to revert the PE and PC lipid composition of circulating Exo towards that of HD and it is the only one of the three biological drugs that did not alter SM expression in MV. Therefore, the determination of lipid alterations of circulating EVs could harbor useful information for the diagnosis and drug response in psoriatic patients.
format Online
Article
Text
id pubmed-9234320
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92343202022-06-28 Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients Paolino, Giovanni Buratta, Sandra Mercuri, Santo R. Pellegrino, Roberto M. Urbanelli, Lorena Emiliani, Carla Bertuccini, Lucia Iosi, Francesca Huber, Veronica Brianti, Pina Prezioso, Caterina Di Nicola, Matteo R. Federici, Cristina Lugini, Luana Front Cell Dev Biol Cell and Developmental Biology Psoriasis is a chronic immune-mediated inflammatory skin disorder affecting children and adults. To date no approved biomarkers for diagnosis of this disease and follow up of patients have been translated into clinical practice. Recently, extracellular vesicles (EVs) secreted by all cells and present in almost all biological fluids are playing a crucial role in diagnosis and follow up of several diseases, including psoriasis. Since many psoriatic patients show altered plasma lipid profiles and since EVs have been involved in psoriasis pathogenesis, we studied the phospholipid profile of EVs, both microvesicles (MV) or exosomes (Exo), derived from plasma of psoriatic patients undergoing systemic biological treatment (secukinumab, ustekinumab, adalimumab), in comparison with EVs of untreated patients and healthy donors (HD). EVs were evaluated by immune electronmicroscopy for their morphology and by NanoSight for their amount and dimensions. EV phospholipid profiling was performed by High Resolution Liquid Chromatography-Mass Spectrometry and statistical Partial Least Squares Discriminant Analysis. Our results demonstrated that psoriatic patients showed a higher concentration of both MV and Exo in comparison to EVs from HD. The phospholipid profile of Exo from psoriatic patients showed increased levels of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol and lysoPC compared to Exo from HD. Sphingomyelin (SM) and phosphatidylinositol (PI) are the only phospholipid classes whose levels changed in MV. Moreover, the therapy with ustekinumab seemed to revert the PE and PC lipid composition of circulating Exo towards that of HD and it is the only one of the three biological drugs that did not alter SM expression in MV. Therefore, the determination of lipid alterations of circulating EVs could harbor useful information for the diagnosis and drug response in psoriatic patients. Frontiers Media S.A. 2022-06-13 /pmc/articles/PMC9234320/ /pubmed/35769256 http://dx.doi.org/10.3389/fcell.2022.923769 Text en Copyright © 2022 Paolino, Buratta, Mercuri, Pellegrino, Urbanelli, Emiliani, Bertuccini, Iosi, Huber, Brianti, Prezioso, Di Nicola, Federici and Lugini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Paolino, Giovanni
Buratta, Sandra
Mercuri, Santo R.
Pellegrino, Roberto M.
Urbanelli, Lorena
Emiliani, Carla
Bertuccini, Lucia
Iosi, Francesca
Huber, Veronica
Brianti, Pina
Prezioso, Caterina
Di Nicola, Matteo R.
Federici, Cristina
Lugini, Luana
Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients
title Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients
title_full Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients
title_fullStr Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients
title_full_unstemmed Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients
title_short Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients
title_sort lipidic profile changes in exosomes and microvesicles derived from plasma of monoclonal antibody-treated psoriatic patients
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234320/
https://www.ncbi.nlm.nih.gov/pubmed/35769256
http://dx.doi.org/10.3389/fcell.2022.923769
work_keys_str_mv AT paolinogiovanni lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT burattasandra lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT mercurisantor lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT pellegrinorobertom lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT urbanellilorena lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT emilianicarla lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT bertuccinilucia lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT iosifrancesca lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT huberveronica lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT briantipina lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT preziosocaterina lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT dinicolamatteor lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT federicicristina lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients
AT luginiluana lipidicprofilechangesinexosomesandmicrovesiclesderivedfromplasmaofmonoclonalantibodytreatedpsoriaticpatients